Malignant neoplasm of parietal lobe
ICD-10 C71.3 is a billable code used to indicate a diagnosis of malignant neoplasm of parietal lobe.
C71.3 refers to a malignant neoplasm located in the parietal lobe of the brain, which is part of the central nervous system (CNS). This type of tumor can arise from glial cells, meningeal tissue, or other neural components. Symptoms may include seizures, sensory deficits, and cognitive changes, depending on the tumor's size and location. Imaging studies, particularly MRI, are crucial for diagnosis, revealing the tumor's size, location, and any associated edema. Molecular markers, such as IDH1/2 mutations and 1p/19q co-deletion status, can provide prognostic information and guide treatment decisions. Treatment typically involves a multidisciplinary approach, including surgical resection, radiation therapy, and chemotherapy. The prognosis varies significantly based on tumor type, grade, and patient factors, making early detection and accurate coding essential for optimal management.
Detailed operative reports, imaging studies, and pathology results.
Surgical resection of a parietal lobe tumor, post-operative follow-up.
Ensure accurate documentation of tumor size, location, and histology.
Comprehensive treatment plans, including chemotherapy and radiation therapy details.
Management of malignant CNS tumors, including chemotherapy regimens.
Document molecular profiling and response to treatment.
Used during surgical resection of a malignant parietal lobe tumor.
Operative report detailing the procedure and findings.
Neurosurgeons must document tumor characteristics and surgical approach.
MRI is the preferred imaging modality for diagnosing malignant neoplasms of the parietal lobe, as it provides detailed images of brain structures and can identify tumor size and associated edema.
